Inavolisib: Regulatory approval in EU for 1L HR+ PIK3CA-mutant metastatic breast cancer in combination with palbociclib and fulvestrant in 2025 (Roche) - Nov 28, 2024 - Bernstein's 23rd Annual Pan European Premium Review Conference
EMA approval • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology
|